Clinical trial of desogestrel and ethinylestradiol tablets in the treatment of perimenopausal dysfunctional uterine bleeding
10.13699/j.cnki.1001-6821.2017.07.007
- VernacularTitle:去氧孕烯炔雌醇片治疗围绝经期功能失调性子宫出血的临床研究
- Author:
Bi-Li ZHANG
1
;
Yi-Jing WANG
;
Xue-Qin ZHANG
Author Information
1. 厦门市妇幼保健院妇产科
- Keywords:
desogestrel and ethinylestradiol tablet;
mifepristone tablet;
perimenopausal dysfunctional uterine bleeding;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(7):599-601
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy and safety of desogestrel and ethinylestradiol tablets in the treatment of perimenopausal dysfunctional uterine bleeding.Methods A total of 54 patients with perimenopausal dysfunctional uterine bleeding were randomly divided into control group and treatment group with 27 cases per group.Control group was orally given mifepristone 10 mg qd for 3 months.Treatment group was given desogestrel and ethinylestradiol tablets 0.17 mg by oral bid for 3 d,then reduced to 0.17 mg qd for 3 cycles with 21 d per cycle.The clinical efficacy,serum follicle stimulating hormone (FSH),luteinizing hormone (LH),estradiol (E2) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment and control groups were 96.23％ (26/27 cases)and 74.07％ (20/27 cases) with significant difference (P ＜0.05).After treatment,the main indexes in treatment and control groups were compared:FSH were (23.27 ±3.05),(36.48 ± 5.13) U · L-1;LHwere (20.03±2.54),(28.36±4.04)U · L-1;E2 were (117.45 ±16.47),(174.75±24.27)pmol · L-1,with significant differences (P ＜ 0.05).The adverse drug reactions in treatment group were based on nausea and dizziness,which in control group were rash,nausea,upper abdominal discomfort.The incidences of adverse drug reactions in treatment and control groups were 7.41％ and 14.81％ without significant difference (P ＞ 0.05).Conclusion Desogestrel and ethinylestradiol tablets have a definitive clinical efficacy in the treatment of perimenopausal dysfunctional uterine bleeding,which can reduce the levels of FSH,LH and E2,without increasing the incidences of adverse drug reactions.
